Original article can be found here – https://www.theaccessgroup.com/en-gb/blog/lgl-taking-law-firm-business-intelligence-to-the-next-level/ This blog explores how law firms can take business intelligence to the next level and why it’s important to do so. It recognises the age-old principle that the legal profession has been built upon: ‘making data pay’. Of course, the way we […]
firm
How I Made It to Law Firm Leadership: ‘When Opportunities Arose, I Said Yes,’ Says Alison Ashmore of Dykema Gossett
Job Title: Member; executive board member. Practice Area: Business Litigation Practice Group. Law school and year of graduation: Baylor Law School, 2007. How long have you been at the firm? Nine years, since February 2013. Alison Ashmore/courtesy photo How long were you a partner at the firm before being promoted to firm leadership? I […]
Law firm suggests govt recognise role of storage in energy regulation
As South Africa takes its first steps towards a just transition and as decarbonisation becomes a strategic imperative for heavy electricity users, the role of energy storage and hybrid technologies is becoming more relevant, says law firm Allen & Overy South Africa. Electricity storage paired with renewable energy generation can […]
Law Firm Career | Law Student Career Journey
Why have you chosen to make your career at Husch Blackwell? I chose Husch Blackwell because of its commitment to diversity, equity & inclusion (DE&I). Through the firm’s DE&I leadership, inclusion is discussed and pushed forward on all levels – the entire depth of what inclusion means, not merely the […]
Kessler Topaz Meltzer & Check, LLP Reminds Investors of C3.ai, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm
RADNOR, Pa., April 22, 2022 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against C3.ai, Inc. (“C3”) (NYSE: AI). The action charges C3 with violations of the federal securities laws, including omissions and fraudulent misrepresentations […]
A Utah law firm acknowledges it’s sharing renter information with landlords. Here’s what it’s telling them.
A powerful Draper law firm that files nearly half of Utah’s eviction cases also keeps a database that some landlords use to screen prospective tenants, according to housing caseworkers and property managers. The law offices of Kirk Cullimore have denied they maintain any kind of “black list,” even as numerous […]
What Law Firm Leaders Need to Know about ESG From Leading Experts | Furia Rubel Communications, Inc.
In this episode of On Record PR, Gina Rubel goes on record with Daniel Smallwood, the head of content for LegalESG.com and the Legal ESG Summit, and Pamela Cone, Social Impact and Sustainability Sage at Amity Advisory. They discuss what ESG is, why it matters, and how law firms can […]
Measuring the Success of a Law Firm Marketing Campaign | Good2bSocial
Extrapolating data about your law firm’s marketing campaigns is very easy; however, interpreting what you learn may leave some feeling lost in a sea of acronyms, numbers, and industry jargon. Most people would see 500 likes on a Facebook post and call it a smashing success. In some cases, it […]
ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses to Inquire About Securities Class Action Investigation – AUPH
Relatlimab is the third immune checkpoint inhibitor from Bristol Myers Squibb, adding to the Company’s growing and differentiated oncology portfolio Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag TM (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved […]
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Relatlimab is the third immune checkpoint inhibitor from Bristol Myers Squibb, adding to the Company’s growing and differentiated oncology portfolio Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag TM (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved […]